Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report.

Murakami S, Yamagishi K, Kitani A, Ueta T, Matsuura Y, Kubota T, Uezono Y

Open source

DOI
10.1177/10966218251385732
Published
2026 Apr
Container
Journal of palliative medicine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/10966218251385732,
  title = {Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report.},
  author = {Murakami S and Yamagishi K and Kitani A and Ueta T and Matsuura Y and Kubota T and Uezono Y},
  year = {2026},
  journal = {Journal of palliative medicine},
  doi = {10.1177/10966218251385732},
  url = {https://doi.org/10.1177/10966218251385732}
}

RIS

TY  - JOUR
TI  - Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report.
AU  - Murakami S
AU  - Yamagishi K
AU  - Kitani A
AU  - Ueta T
AU  - Matsuura Y
AU  - Kubota T
AU  - Uezono Y
PY  - 2026
JO  - Journal of palliative medicine
DO  - 10.1177/10966218251385732
UR  - https://doi.org/10.1177/10966218251385732
ER  - 

APA

S, M., K, Y., A, K., T, U., Y, M., T, K., & Y, U. (2026). Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report.. Journal of palliative medicine. https://doi.org/10.1177/10966218251385732

Source records